Tag: MYRY

Biotech Reviews & More


BioSig Technologies, Inc. BSGM

We began tracking many stocks with coronavirus synergies back in the late winter and early spring this year, as the global threat was still in the earlier stages of emergence. Our first alert on BSGM was on April 7th, and the stock would go on to run from under $4 to more than $12,

In the last few weeks, BSGM has finally begun to come down off of those highs, and we are now interesting in tracking it more closely for a potential bottom bounce. We’ll be looking out for the stock to establish support, and possibly make another significant run in coming weeks.
_____

iBio, Inc. IBIO

Speaking of coronavirus related stocks that have done well, IBIO was among those that we have been tracking since word of the pandemic began to spread widely, and we have seen a very nice move from it as well.

Following our most recent mention on March 17th, the stock saw  a low of .76, and to finish off last week it hit a new high of 2.69. That’s a 254% increase, and a perfect example of the kind of impetus that the virus has provided to a lot of these mid-sized biotechs.

Ideanomics, Inc. IDEX

We took notice of an interesting situation with IDEX currently transpiring. Last week, the stock tumbled on word of a possible class action suit currently being investigated. Today, it’s bouncing back in the premarket after the company announced the delivery of more than $3M in Chinese EV orders.

We’ll be interested to track its progress out of the gate as we kick off a fresh trading week today, without any notable earnings reporters on the calendar.

Extended Watchlist:
ITRM, LVXI, MYRY, PVDG, DECN, BHTG,

Medical Marijuana Round-Up Report Vol. IV

It’s time again for yet another installment of our Medical Marijuana Round-Up Report, when we take a look at all of the plays that we’ve been tracking for the past several months in the rapidly burgeoning cannabis industry. Since early this fall, we have been able to achieve incredible percentage gains from this group of cannabis stocks:

Hemp, Inc. HEMP

When we initially began covering HEMP, the stock was as low as .027. It made a solid run all the way up to .09 before consolidating to bounce off of .037, at which point we saw another jump to .065. Consolidation occurred yet again, however it has rarely dipped below our price at coverage initiation of .027.

Yesterday, the stock surged as much as 37%, running into resistance at the 50DMA (also the HOD) of .037. It ended up closing at .034, a 23% gain on the day. In order to see some added gains here we need to breach the 100 & 50DMA’s at .036 & .037.
___

Medical Marijuana, Inc. MJNA

MJNA has been a freight train over the past several days; we’ve seen positive moves every single day this week. Having broken through it’s previous high in the .16’s on Wednesday, the stock entered blue-sky breakout mode, and has traded extremely high volume over the past three sessions.

There is a lot of momentum in this stock, however when we do see a pullback, we’d like to have the previous resistance level at .162 hold as a future level of support. Below that, we have the 20DMA as support at .14. Volume of this magnitude for the latter portion of the week, is sure to spill over into Monday, so it is highly likely that MJNA will be at or near the tops of our watchlists.

___

Cannabis Science, Inc. CBIS

The first time we mentioned CBIS, we saw a 150% spike from .04-.10. Since then it has held support at .048, and yesterday we had a high, momentum-fueled bounce. The stock broke through the 20, 50 & 100DMA’s and ran into resistance at the 200DMA of .06, where it closed. That represents a gain of 25% from our recent support level.

CBIS is originator the Phytiva line of hemp-based products that was recently acquired by our next big winner, XCHC.

___

X-Change Corporation XCHC

We began talking about XCHC on Monday, having not dropped our focus from it all week, and were duly rewarded for our persistence. Monday’s session brought a move opened from .0699 to .079 (+13%), pulled back to a low of .056, before running back to .0699 (+25%), bringing in a total of 38% on our first day of coverage.

On Wednesday it saw a low of .0521, and surged rapidly yesterday to hit a high of .075, representing an added gain of 44%, and bringing our cumulative gains for the week to a very respectable 82%

Yesterday’s News:

DALLAS, Jan. 31, 2013 /PRNewswire via COMTEX/ — X-Change Corporation (OTCQB:XCHC), a U.S. publicly-traded company, through its European joint venture with Dupetit Natural Products, GmbH, announces that within one week the Company will move into the testing stage of development of its unique hemp-based Phytiva brand of products, as the Company prepares to bring these products to European and North American markets.

___

Foy-Johnston, Inc. FOYJ
While not cannabis-related, we had to make a quick mention of FOYJ, our point of focus for yesterday’s session. We began monitoring the stock on Jan.14-15th when it appeared in our extended watchlist with a price as low as .0006.

Yesterday FOYJ gapped up to .0019 from the previous day’s close of .0014. It ran to .0024 before it dipped to low of .0013, and followed that with a bounce as high as .0018. For the ones lucky enough to catch the .0006 bottom, you could have been looking at gains in excess of 300% at yesterday’s high. During that process, savvy timing on subsequent bounces could have brought gains of as much as 65%

__

Extended Watchlist:
APPA, MYRY, ABIO, TSYS, HEB, PACD, SIPC

BMSN, KERX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN has been a main point of focus for us this year. We first began paying close attention to BMSN towards the end of 2012 when it was trading as low as .0003. Yesterday, the stock had another rockstar performance, reaching new highs and cracking through another major resistance point at .0035 (200DMA).

After the initial surge we saw from .0003-.0024, we wanted to see support hold off of .001. Now that we have hit new highs, we are raising the bar and looking for new support to hold  at .0035, or below that, the 20DMA of .0021. If we can see these areas hold as support, we are going to remain bullish on BMSN.

Over the span of our coverage on BMSN, we have been afforded the opportunity at an accumulation of up to 1400% in possible gains from .0003 to yesterday’s high of .0045

Most Recent News:

SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.

__

Keryx Biopharmaceuticals, Inc. KERX

KERX earned us a spot in the Penny Stock Rumble on Tuesday, racking up another solid day of gains, and hitting a high of 8.79. That brings our total possible profits to a very respectable 154%

We are going to be monitoring the activity on KERX following yesterday’s announcement regarding the comnpany’s planned $55M public offering.

Yesterday’s News:

NEW YORK, Jan. 29, 2013 /PRNewswire via COMTEX/ — Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.

__

Extended Watchlist:
SCXN, ITNS, MYRY, SWVI, ONCI, ENTB